ToxStrategies is excited to be returning to present and exhibit at The Society of Toxicology’s Annual Meeting, March 19^th through March 23^rd.  The meeting is in Nashville, TN, at the Music City Center

Come by and see us at Booth #628!

Poster Presentations

• A Tiered Approach for Assessing the Safety of Polymeric Ingredients in Cosmetics and Personal Care Products; L. Brown, D.A. McMillan, J.D. Urban, and A.L. Mihalchik
• Reliability Assessment of Guideline-Based Studies Using Systematic Review Critical Appraisal Tools; N.Y. Choksi, S. Fitch, M.A. Harris, C.M. Thompson, and D.S. Wikoff
• Using NHANES Data to Characterize the Magnitude of Allostatic Load in Vulnerable Communities: Impact to Existing Risk Assessment Uncertainty/Variability Factors; A. East, W. Rish, and W.D. Klaren
• Development of a Study Quality Tool for Use in a Systematic Review of Literature Reporting Microplastic Exposure and Reproductive and Developmental Toxicity; S. Fitch, J. Rogers, S. Marty¹, R. Ellis-Hutchings¹, R. Becker², and D. Wikoff; 1 Dow Chemical Company, Midland, MI; 2 American Chemistry Council, Washington, DC
• Risk Assessment of Three Smoke Flavoring Primary Products Currently Under Re-Evaluation by EFSA; A.C. Franzen, C.M. Thompson, G.P. Brorby, D.S. Wikoff, Z. Ilkbahar¹, C. Doepker; 1 Kerry Inc., Naas, Ireland
• Updated Mode of Action Information Informing the Risk Assessment of HFPO-DA (GenX); L.C. Haws, M.M. Heintz, and C.M. Thompson
• Assessment of the Mode of Action Underlying Development of Liver Lesions in Mice Following Oral Exposure to HFPO-DA (GenX) and Relevance to Humans; M.M. Heintz, L.C. Haws, and C.M. Thompson
• In Vitro Transcriptomic Analyses Informing the Mode of Action of HFPO-DA (GenX) in the Liver; W.D. Klaren, M.M. Heintz, A.W. East, C.M. Thompson, and L.C. Haws
• Weight-of-Evidence Evaluation of Endocrine Activity for Di-Isodecyl Phthalate (DIDP) and Di-Isononyl Phthalate (DINP); I.A. Lea, M.M. Heintz, D. Feifarek, L.C. Haws, and S.J. Borghoff
• Toward Best Practices for Read-Across in Evaluation of Drug Impurities, Extractable, and Leachable Compounds; A.L. Mihalchik, N.Y. Choksi, and M.L. Wood
• Relative Oral Bioavailability of Manganese in Electric Arc Furnace Steel Slag is Influenced by High Iron Content and Low Bioaccessibility; D.M. Proctor, S. Vivanco, and A. Blanchette
• The Influences of Household Behavior, Environmental, and Demographic Factors on Indoor and Outdoor Air Quality; B.N. Rivera, L. Bramer¹, C.C. Ghetu², D. Rohlman³, K. Adams², K. Waters¹, and K.A. Anderson²; 1 – Pacific Northwest National Laboratory, Biological Sciences Division, Richland, WA; 2 – Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR; 3 – College of Public Health and Human Sciences, Oregon State University, Corvallis OR
• Scoping Review of the Immunomodulatory Effects of Cannabidiol: Effects within T cells; B.N. Rivera, A. Svetlik¹, W.D. Klaren, D.S. Wikoff, and R.G. Henderson; 1 – Texas A&M University, College Station, TX
• An Evaluation of Risk Assessments on Hexavalent Chromium [Cr(VI)]: The Past, Present, and Future of Mode of Action Research; C.M. Thompson, D.S. Wikoff, D.M. Proctor, and M.A. Harris

Continuing Education

• Tailoring Off-the-Shelf Systematic Review Methods to the Identification and Evaluation of Mechanistic Data, Dr. Daniele Wikoff, Sunday, March 19^th, 8:15 AM, Music City Center, Room 202

Exhibitor Hosted Session

• Modern Strategies to Evaluate Drug Impurities, Drs. Amy L. Mihalchik, DABT, R.A.C., Neepa Y. Choksi, Isabel Lea, and Marcie L. Wood, Monday, March 20^th, 12:00 PM, Music City Center, Room 101A.
  • Evaluation of drug impurities is a critical, occasionally overlooked aspect of drug safety. ToxStrategies consultants will present case studies of strategies and tools used to address safety of impurities present in prescription and non-prescription drugs, including targeted literature searches, read-across, and QSAR approaches.
  • Participants will learn essential strategies to evaluate impurities in prescription and non-prescription drugs, and overall considerations to effectively support the safety of data-rich and data-poor impurities, including criteria for valid read-across rationales and integration of QSAR methods in drug impurity safety assessment.

Workshop and Symposium Sessions

• Continuing Towards Best Practices in Organizing, Assessing, and Applying Mechanistic Data in Hazard Characterization and Risk Assessment, Dr. Daniele Wikoff, Tuesday, March 21^st, 8:00 AM, Music City Center, Karl Dean Ballroom
• Placental Biology, Toxicology, and In Vitro Modeling for Predictive Developmental Toxicology, Dr. John M. Rogers, Tuesday, March 21^st, 1:00 PM, Music City Center, Karl Dean Ballroom
• Refining Inhalation Risk Assessments by Integrating New Approach Methodologies, Dr. William D. Klaren, Thursday, March 23^rd, 8:30 AM, Music City Center, Room 207B

Educational-Career Development Session

• A Day in the Life of an Industry Toxicologist, Dr. Allison Franzen, Wednesday, March 22^nd, 11:00 AM, Music City Center, Room 202

For a complete agenda of sessions and presentations click here.